Caleb Rans, PharmD

Contributing Writer https://www.hematologyadvisor.com

Caleb Rans is a clinical pharmacist and medical communications specialist with professional expertise in medical writing, editing, and contract clinical research. He holds a PharmD from the University of Alberta and presently resides in Vancouver, Canada. He currently works as an independent consultant for several news, CME, and pharmaceutical companies.

All articles by Caleb Rans, PharmD

Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.

General Hematology

Current and Prospective Treatment Strategies for Myeloproliferative Neoplasms

Caleb Rans, PharmD

September 17, 2019

Several novel treatment agents for myeloproliferative neoplasms are currently being studied in phase 1 or phase 2 trials.

Myelodysplastic Syndromes

Novel Management Strategies for Myelodysplastic Syndromes

Caleb Rans, PharmD

August 29, 2019

Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.

The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.

Lymphoma

Real-World Data in the Era of Precision Medicine for Lymphoid Malignancies

Caleb Rans, PharmD

August 15, 2019

The use of real-world data shows promise in guiding the development of management strategies for lymphoid malignancies.

Half of patients with MDS require regular blood transfusions.

Thalassemias

Reducing Transfusion Burden and Addressing Unmet Needs in Beta Thalassemia

Caleb Rans, PharmD

August 8, 2019

Lack of resources and poor awareness of thalassemia can make it difficult for patients with beta thalassemia to receive necessary blood transfusions.

Group O Rh(D)-negative blood cells can be administered to patients with any ABO Rh(D) type, making them a valuable but limited resource.

Bleeding Disorders

Recommendations for Optimizing the Use of Group O Red Blood Cells in Transfusions

Caleb Rans, PharmD

July 23, 2019

Group O Rh(D)-negative blood cells can be administered to patients with any ABO Rh(D) type, making them a valuable but limited resource.

In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.

Lymphoma

Current and Prospective Treatment Strategies for Follicular Lymphoma

Caleb Rans, PharmD

July 19, 2019

In addition to current obinutuzumab- and rituximab-based treatment regimens, several novel agents have received approval for follicular lymphoma treatment.